Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer

Oncology

Volumn 74, Issue 1-2, 2008, Pages 7-11

  Oshita, Fumihiro ^a   Saito, Haruhiro ^a   Yamada, Kouzo ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Amrubicin; Chemotherapy; Irinotecan; Small cell lung cancer

Indexed keywords

AMRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LUNG SMALL CELL CANCER; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 46249101493     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000138350     Document Type: Article

References (17)

1. Horiike A, Saijo N: Small-cell lung cancer: current therapy and novel agents. Oncology 2005;19:47-52.
2. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-1229.
3. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998;16:1068-1074.
4. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
5. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T: A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 1998;89:1229-1238.
6. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M: Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 1989;80:69-76.
7. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y: Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 1998;89:1061-1066.
8. Yana T, Negoro S, Takada Y, Yokota S, Takada Y, Sugiura T, Yamamoto H, Sawa T, Kawahara M, Katakami N, Ariyoshi Y, Fukuoka M: Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:253-258.
9. Takigawa N, Takeyama M, Shibayama T, Tada A, Kawata N, Okada C, Aoe K, Kozuki T, Hotta K, Tabata M, Kiura K, Ueoka H, Tanimoto M, Takahashi K: The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells. Oncol Rep 2006;15:837-842.
10. Masuda N, Matsui K, Negoro S, Takifuji N, Takeda K, Yana T, Kobayashi M, Hirashima T, Kusunoki Y, Ushijima S, Kawase I, Tada T, Sawaguchi H, Fukuoka M: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998;16:3329-3334.
11. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909-913.
12. Yamada K, Ikehara M, Tanaka G, Nomura I, Oshita F, Noda K: Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807). Oncology 2004;66:94-100.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
14. National Cancer Institute-Common Toxicity Criteria, version 3. http://ctep.cancer.gov/reporting/CTC-3.html.
15. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-861.
16. Blackstein M, Eisenhauer EA, Wierzbicki R, Yoshida S: Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1990;8:385-389.
17. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, Saijo N, Fukuoka M, Ariyoshi Y: Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005;16:430-436.